Related Experiment Videos
Metabolism of dynorphin A(1-13)
1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville 32610, USA.
Die Pharmazie
|June 24, 2004
Summary
Dynorphin A(1-13) shows potential for opiate withdrawal and pain relief but is rapidly metabolized. Chemical modifications can enhance its stability in human plasma and cerebrospinal fluid (CSF).
Area of Science:
- Neuroscience and Pharmacology
- Peptide Metabolism and Stability
Background:
- Dynorphin A(1-13), an endogenous opioid peptide, exhibits modest efficacy in alleviating mild opiate withdrawal symptoms in humans.
- Dynorphin has demonstrated the ability to potentiate morphine's analgesic effects in preclinical models of morphine tolerance.
Purpose of the Study:
- To review the metabolism of dynorphin A(1-13) in human plasma and cerebrospinal fluid (CSF).
- To discuss the limitations of dynorphin A(1-13) as a therapeutic agent due to rapid enzymatic degradation.
Main Methods:
- Review of existing literature on dynorphin A(1-13) metabolism.
- Analysis of studies investigating chemical modifications to enhance peptide stability.
Main Results:
- Dynorphin A(1-13) undergoes extensive metabolism by human enzymes, leading to a very short in vivo half-life (less than one minute).
- Specific chemical modifications, including N-methylation of Tyr1 and C-terminal amidation, effectively protect dynorphin A(1-13) from proteolytic degradation in human plasma.
Conclusions:
- The rapid metabolism of dynorphin A(1-13) significantly limits its therapeutic potential.
- Chemical modifications offer a promising strategy to overcome metabolic instability and improve the pharmacokinetic profile of dynorphin A(1-13) for clinical applications.